STAT+: Survival rates for cancer patients on immunotherapy depend on insurance coverage, study finds
\n \t
\n
<\/BR>
\n
\n \t
\n
<\/BR><\/p>\n
As a cancer patient, access to innovative drugs can help extend your life \u2014 that is if you have health insurance, a new study finds.<\/p>\n
In a JAMA Open Network study published Monday<\/a>, researchers from the American Cancer Society found that the introduction of immune checkpoint inhibitors in advanced-stage cancer patients improved survival for patients across all insurance types. However, there was a significant widening of the survival gap between privately insured patients and uninsured. The two-year survival rate of privately insured patients (with melanoma) jumped from nearly 29% to 46%, whereas in uninsured patients, the survival rate increased from about 16% to just over 28%.<\/p>\n \u201cIf you give people good, high-quality care, people stop dying. That\u2019s it, it\u2019s that simple,\u201d said Otis Brawley, an oncology professor at Johns Hopkins University School of Medicine, who was not involved in the study.<\/p>\n Continue to STAT+ to read the full story\u2026<\/a><\/p>\n<\/div>\n